The document is a regulatory intimation regarding the availability of a transcript for a conference call with analysts and investors.
The call was focused on the discussion of the company's Audited Financial Results for the quarter and year ended 31st March, 2026.
The transcript has been made available on the company's website at the provided URL: https://torrentpharma.com/pdf/investors/Q4-FY25-26_Earnings-Call-Transcript.pdf.
The filing is made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The letter is a follow-up to previous communications dated 12-May-26 and 16-May-26.
No management participants, dial-in details, or specific commentary from the call are disclosed in this announcement.
Additional Notes Section
This announcement itself contains no financial highlights, guidance, or presentation summaries.
The purpose of this specific document is solely to comply with regulatory disclosure requirements by intimating the exchanges that the transcript is now publicly available.
The document explicitly states that it is a compliance filing and does not contain any unpublished price sensitive information (UPSI).
